Resources Repository
-
ArticlePublication 2007Modeling HPV and Cervical Cancer in the U.S. for Analyses of Screening and Vaccination
This paper discusses a model of human papillomavirus (HPV) and cervical cancer that incorporates uncertainty …
This paper discusses a model of human papillomavirus (HPV) and cervical cancer that incorporates uncertainty about the natural history of disease that was used to provide quantitative insight into U.S. policy choices for cervical cancer prevention. The authors developed a stochastic microsimulation of cervical cancer that distinguishes different HPV types by their incidence, clearance, persistence, and progression. For each set of sampled input parameters, likelihood-based goodness-of-fit (GOF) scores were computed based on comparisons between model-predicted…
Microsimulation | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Clinical Care | Science/Technology | North America -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Health/Medicine | Policy/Regulation | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Health Outcomes | Value of Information | Health/Medicine | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | North America -
ArticlePublication 2024Hepatitis C Elimination in Rwanda: Progress, Feasibility, Economic Evaluation
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis …
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis C virus (HCV) and identifies strategies to achieve World Health Organization (WHO) elimination goals by 2030. Employing a microsimulation model spanning 2015 to 2050, the analysis assesses HCV epidemic trends, prevalence, mortality, and total care costs under various scenarios. Results show that between 2018 and 2022, over 7 million people were screened and 60,000 treated, projecting Rwanda's potential achievement of…
Microsimulation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Sub-Saharan Africa -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Mathematical Models | Health/Medicine | Chronic Disease/Risk | Evidence Synthesis | Cost-Effectiveness Analysis | Europe -
ArticlePublication 2023New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, Cost-Effectiveness
This study presents a microsimulation model designed to estimate the health effects, costs, and cost-effectiveness …
This study presents a microsimulation model designed to estimate the health effects, costs, and cost-effectiveness of interventions for type 2 diabetes in the United States. Unlike existing models that rely on UK data, this model incorporates newly derived risk equations based on US studies, enhancing its applicability to the US context. The model features a highly modular architecture allowing for easy addition of new modules and interventions, facilitating policy decision-making. Internal validation showed good performance,…
Microsimulation | Health/Medicine | Chronic Disease/Risk | Cost-Effectiveness Analysis | North America -
Tutorial/PrimerPublication, Teaching Resource 2023Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: Tutorial
The study examines the utility of excess hazard (EH) methods in reducing model uncertainty when …
The study examines the utility of excess hazard (EH) methods in reducing model uncertainty when estimating long-term survival in cost-effectiveness analyses. Using a case study of breast cancer patients, standard parametric survival models were compared with EH methods incorporating general population mortality rates, with and without a cure parameter. Results showed substantial variability in survival extrapolations across standard models, while EH methods, particularly EH cure models, significantly reduced uncertainty. Long-term treatment effects approached null for…
Mathematical Models | Health/Medicine | Chronic Disease/Risk | Cost-Effectiveness Analysis | Europe -
BriefPublication 2023Simulation Modeling to Guide Priority Setting in Global Maternal Health
This study developed the Global Maternal Health (GMatH) microsimulation model to evaluate maternal health policy …
This study developed the Global Maternal Health (GMatH) microsimulation model to evaluate maternal health policy interventions across 200 countries and territories from 1990 to 2050. It addresses challenges in measuring maternal mortality by simulating individual women's reproductive lifecycles. Various interventions, including family planning and facility-based care, were simulated to compare against a baseline scenario projecting the global maternal mortality ratio (MMR) to decrease to 167 per 100,000 live births by 2030. Results suggest that while…
Microsimulation | Health/Medicine | Policy/Regulation | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Global -
ArticlePublication 2021Racial and Ethnic Inequities in the Early Distribution of U.S. COVID-19 Testing Sites and Mortality
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to …
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to provide data that would contribute to understanding transmission. This research explored how these sites were distributed in relation to racial and ethnic demographics and its connection to observed disparities in COVID-19 outcomes. Data from mid-April to late May 2020 revealed that testing sites were not equally distributed among racial groups. Specifically, there was an overrepresentation of testing sites in areas…
Health Outcomes | Health/Medicine | Policy/Regulation | Test Performance | Infectious Diseases | Social Determinants | Culture/Society | Science/Technology | North America